Fovinaciclib for First-Line Therapy of Advanced Breast Cancer

医学 内科学 临床终点 中期分析 随机对照试验 乳腺癌 安慰剂 芳香化酶抑制剂 肿瘤科 激素疗法 癌症 临床试验 意向治疗分析 生活质量(医疗保健) 转移性乳腺癌 不利影响 妇科 性能状态 比例危险模型 来曲唑 外科 生存分析 激素替代疗法(女性对男性) 全身疗法 激素疗法
作者
Peng Yuan,Liu Y,Wei Li,Huiping Li,Zhongsheng Tong,Jing Cheng,Mingjuan Zhang,Jinlu Shan,Jincai Zhong,Tienan Yi,Jian Liu,Huihui Li,Z H Huang,Jinsheng Wu,Sijuan Ding,Liang Li,Hong Zong,Hongyan Jia,Shusen Wang,Kun Wang
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:12 (8): 855-855
标识
DOI:10.1001/jamaoncol.2026.1938
摘要

Importance: Approximately 70% of patients with breast cancer (BC) have hormone receptor-positive, human epidermal growth factor receptor 2 (ERBB2; formerly HER2)-negative disease. Objective: To evaluate the efficacy and safety of fovinaciclib plus an aromatase inhibitor as first-line treatment for hormone receptor-positive, ERBB2-negative advanced BC. Design, Setting, and Participants: This double-blind, phase 3 randomized clinical trial enrolled patients from March 2, 2022, to June 28, 2023, from 63 centers in China. Eligible patients were adult women with hormone receptor-positive, ERBB2-negative advanced BC and no history of systemic therapy for advanced disease. The data cutoff date was June 25, 2024. Data were analyzed from September to October 2024. Intervention: Patients were randomized (1:1) to receive fovinaciclib, 200 mg (orally once daily on days 1 to 21), or placebo plus letrozole, 2.5 mg, or anastrozole, 1 mg (orally once daily on days 1 to 28), in 28-day cycles. Premenopausal or perimenopausal patients also received goserelin, 3.6 mg (subcutaneously on day 1). Main Outcomes and Measures: The primary end point was progression-free survival (PFS) per blinded independent central review (BICR). Secondary end points included other efficacy end points and safety. Exploratory end points included overall survival (OS) and quality of life. Results: Of 417 randomized female patients, the median (range) age was 57.0 (32-84) years. A total of 208 were randomized to the fovinaciclib arm and 209 to the placebo arm. At prespecified interim analysis (median [range] follow-up, 16.6 [0.3-27.8] months), a significantly prolonged median PFS was observed with fovinaciclib compared with placebo (not reached vs 20.2 months [95% CI, 16.4 months to not evaluable]; hazard ratio, 0.55; 95% CI, 0.38-0.77; 1-sided P < .001) per BICR assessments. Consistent PFS benefit was observed in most patient subgroups. Fovinaciclib was also favored across secondary efficacy end points. OS data were immature, with only 40 events (9.6%). The most common treatment-emergent adverse events were hematologic toxic effects, none of which led to serious adverse events or study drug discontinuation. Incidence of discontinuation due to treatment-emergent adverse events was only 1.4% in both arms (3 of 208 receiving fovinaciclib and 3 of 209 receiving placebo). Longitudinal changes in global health status, function domains, and symptom domains of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 were similar between the 2 arms. Conclusions and Relevance: In this randomized clinical trial, adding fovinaciclib to first-line aromatase inhibitor conferred significant and clinically meaningful PFS benefit and consistent improvements in other efficacy outcomes, along with manageable safety and unaffected quality of life. Trial Registration: ClinicalTrials.gov Identifier: NCT05439499.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
爱听歌秋尽完成签到,获得积分10
1秒前
1秒前
Eli发布了新的文献求助10
2秒前
2秒前
可爱的函函的应助被Serendipity采纳,获得10
2秒前
tutu发布了新的文献求助10
3秒前
ddt完成签到,获得积分10
3秒前
4秒前
无条件完成签到,获得积分10
4秒前
asd2221发布了新的文献求助10
4秒前
糖醋排骨完成签到,获得积分10
5秒前
5秒前
ocean完成签到,获得积分10
5秒前
7秒前
RAN18完成签到,获得积分10
7秒前
清爽的莆完成签到 ,获得积分10
7秒前
豆豆豆豆完成签到,获得积分10
8秒前
daomaihu发布了新的文献求助100
8秒前
荼蘼发布了新的文献求助10
8秒前
4645发布了新的文献求助10
8秒前
9秒前
Maestro_S的应助被zone采纳,获得10
9秒前
廖玲丽完成签到 ,获得积分10
10秒前
10秒前
11秒前
tang发布了新的文献求助10
11秒前
11秒前
milion完成签到,获得积分10
11秒前
star完成签到,获得积分10
11秒前
13秒前
易怀亮完成签到,获得积分10
13秒前
Luxi发布了新的文献求助10
13秒前
13秒前
13秒前
Z_Z完成签到,获得积分0
13秒前
cs完成签到,获得积分10
14秒前
tutu发布了新的文献求助10
14秒前
万物更始完成签到,获得积分10
14秒前
在水一方的应助被Eli采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566975
关于积分的说明 21789458
捐赠科研通 7769647
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241